Navigation Links
Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
Date:4/22/2013

ooking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission
'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
2. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
3. Oramed Pharmaceuticals Announces Reverse Stock Split
4. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
5. Trigemina to Present at the 2013 BIO International Convention
6. Infinata’s BioPharm Insight to Offer Exclusive Preview of 2013 Key Reports at the BIO International Conference and Partnerships in Clinical Trials
7. Campbell Alliance to Release New Forward-Looking Industry Report on Deal-Making Trends at the 2013 BIO International Convention
8. 20 Swiss Biotech Firms and Organizations will Populate the Swiss Pavilion at BIO 2013 International Convention
9. Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
10. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
11. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOULDER, Colo. , Jan. 23, 2015  Array BioPharma ... it has reached a definitive agreement with Novartis Pharma ... BRAF inhibitor currently in Phase 3 development.  This agreement is ... and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
(Date:1/22/2015)... zFlo Motion , a US leader in ... product from a new partner. STT-Systems has developed ... 15 years, with offerings in the optical-motion capture, 3D scanning, ... (inertial measurement unit), iSen, is opening eyes around the world. ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... Driven by the burgeoning demand from drug discovery research and high ... projected to amount to $5.0 billion by 2015. A key driving ... screening thousands of compounds. , ... San Jose, CA ...
... Oregon researchers have synthesized an elusive metal-hydroxide compound ... the way for improved precursor inks that could ... key to a "bottom-up" production of possibly the ... of nitroso-butylamine as an additive in place of ...
... N.J., Oct. 31 Memory,Pharmaceuticals Corp. (Nasdaq: ... Panel has granted the Company,s request for an,extension ... NASDAQ Capital Market,minimum market capitalization requirement of $35 ... stockholders, equity in order to remain,listed. There can ...
Cached Biology Technology:Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc 2Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc 3New nanocluster to boost thin films for semiconductors 2Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2
(Date:1/22/2015)... and POINT ROBERTS, Washington , January ... covering leading sectors including technology and tech stocks, releases video ... featuring master pickpocket and security consultant Apollo Robbins . ... and talks about the Wocket™ biometric smart wallet, a product ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its ... the G2 model. The G2 sets a higher standard for ... human capital management solution. With plug-and-play installation, touch screen interface ... clock provides a robust time collection solution for the small ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... Understanding macrophages could lead to ways to prevent HIV-associated ... cause dementia in HIV patients, University of Florida and ... , Macrophages, long-living white blood cells often considered the ... part of the brain where many memories are stored ...
... the University of Warwick's horticultural research arm Warwick HRI have ... that will provide a massive boost to the world's plant ... of its type in the world and will provide researchers ... up a new spin out company "Warwick Plant Genomic Libraries ...
... immune therapy for breast cancer , A team from ... that by using a cancer vaccine based on the ... breast tumors. Cancer vaccines, which are more properly described ... tumor-associated antigens. , Using Listeria, the researchers, led ...
Cached Biology News:Scavenger cells could be key to treating HIV-related dementia 2Scavenger cells could be key to treating HIV-related dementia 3New plant DNA libraries provides massive boost to world's plant researchers 2Breast tumors in mice eradicated using cancer vaccine 2Breast tumors in mice eradicated using cancer vaccine 3
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: